First Tracks Biotherapeutics Inc AI Stock Analysis
Want to see TRAX full AI Analyst Report?
First Tracks Biotherapeutics Inc (TRAX) AI Stock Analysis
First Tracks Biotherapeutics Inc
(NASDAQ:TRAX)
The score is held down primarily by weak financial performance (no revenue, large and worsening losses, and significant cash burn), which raises ongoing funding risk. Technical momentum is a meaningful offset (price above key moving averages with a positive MACD), but valuation support is limited due to negative earnings and no dividend yield data.
First Tracks Biotherapeutics Inc (TRAX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.87B
- Dividend Yield
- ―
- Average Volume (3M)
- 827.07K
- Price to Earnings (P/E)
- -9.9
- Beta (1Y)
- 0.48
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 104
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
First Tracks Biotherapeutics Inc Business Overview & Revenue Model
Company Description
First Tracks Biotherapeutics, Inc., situated in San Diego, California, specializes in pioneering new immunology-based treatments. The firm is actively involved in the discovery and progression of therapeutics aimed at combating autoimmune and inflamm...
First Tracks Biotherapeutics Inc Financial Statement Overview
Summary
Financial fundamentals are weak: no revenue reported across 2023–2025, persistent and worsening net losses (-$166.1M in 2025 vs. -$163.7M in 2024 and -$106.2M in 2023), and heavy operating cash burn (-$142.9M in 2025). The main positive is low leverage (debt-to-equity ~0.04–0.05), but the declining equity base increases future financing/dilution risk.
Income Statement
14Very NegativeBalance Sheet
63PositiveCash Flow
24Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | -1.20M | -139.61M | -152.34M | 0 |
| EBITDA | -119.27M | -176.58M | -178.70M | -116.08M |
| Net Income | -115.21M | -166.09M | -163.71M | -106.15M |
Balance Sheet | ||||
| Total Assets | 170.46M | 330.55M | 441.89M | 444.11M |
| Cash, Cash Equivalents and Short-Term Investments | 155.63M | 311.64M | 385.37M | 390.90M |
| Total Debt | 3.77M | 14.11M | 16.04M | 17.81M |
| Total Liabilities | 19.45M | 43.05M | 50.30M | 34.26M |
| Stockholders Equity | 151.01M | 287.49M | 391.60M | 409.85M |
Cash Flow | ||||
| Free Cash Flow | -81.57M | -143.01M | -126.16M | -93.81M |
| Operating Cash Flow | -81.53M | -142.93M | -125.81M | -93.00M |
| Investing Cash Flow | 34.96M | 228.03M | 95.40M | 144.75M |
| Financing Cash Flow | -36.00M | 30.01M | 117.52M | -87.09M |
First Tracks Biotherapeutics Inc Peers Comparison
Overall Rating
XNCR61Neutral
REPL55Neutral
TRAX49Neutral
KURA48Neutral
CTMX46Neutral
ALLO40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 61Neutral | $2.55B | -21.66 | -21.29% | ― | 33.55% | 11.51% | |
| 55Neutral | $1.82B | -6.89 | -157.78% | ― | ― | 19.12% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | $1.87B | -9.90 | -72.93% | ― | ― | ― | |
| 48Neutral | $675.31M | -2.23 | -336.24% | ― | -23.76% | -33.09% | |
| 46Neutral | $446.91M | -4.54 | -33.97% | ― | -87.66% | -210.45% | |
| 40Underperform | $231.06M | -1.06 | -49.84% | ― | ― | 36.37% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TRAX | First Tracks Biotherapeutics Inc | 44.46 | 25.46 | 134.00% | |
| XNCR | Xencor Inc. | 34.01 | 17.27 | 103.17% | |
| CTMX | CytomX Therapeutics Inc. | 2.05 | -1.92 | -48.36% | |
| KURA | Kura Oncology | 7.35 | -4.38 | -37.34% | |
| REPL | Replimune Group | 19.23 | 9.84 | 104.79% | |
| ALLO | Allogene Therapeutics | 0.67 | -0.68 | -50.67% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 29, 2026
